Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Gurney

Showing results (31-40 of 135) with videos related to

Pageof 14
Sort By:
BJU International|July 25, 2013
Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancerAndy C M Won, Howard Gurney, Gavin Marx, et al.
Asia-Pacific Journal of Clinical Oncology|March 3, 2022
Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific regionMasatoshi Eto, Jae-Lyun Lee, Yen-Hwa Chang, et al.
Journal of Mass Spectrometry : JMS|July 30, 2020
Evaluating bioanalytical capabilities of paper spray ionization for abiraterone drug quantification in patient plasmaAtul Bhatnagar, Matthew J McKay, Malmaruha Arasaratnam, et al.
Neuropsychological Rehabilitation|March 4, 2026
Changes in perceived cognitive functioning following a codesigned online group cognitive rehabilitation for prostate cancer survivors on androgen deprivation therapy: Series of single-case experimental designsLorna Pembroke, Kerry A Sherman, Haryana M Dhillon, et al.
Cancer Chemotherapy and Pharmacology|May 14, 2019
Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancerMalmaruha Arasaratnam, Megan Crumbaker, Atul Bhatnagar, et al.
Seminars in Oncology Nursing|July 25, 2024
Online Group Cognitive Rehabilitation Program for Prostate Cancer Survivors: Development Using Codesign and the Theoretical Domains FrameworkLorna Pembroke, Kerry A Sherman, Haryana M Dhillon, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 22, 2024
What is the nature and impact of cognitive difficulties following hormonal treatments for prostate cancer?: An interpretative phenomenological analysisLorna Pembroke, Kerry A Sherman, Haryana M Dhillon, et al.
The Medical Journal of Australia|January 28, 2023
Dual-energy x-ray absorptiometry assessment of bone health in Australian men with prostate cancer commencing androgen deprivation therapyMariya F Hamid, Amy Hayden, Tania Moujaber, et al.
Cancer Treatment Reviews|September 14, 2010
Moving towards dose individualization of tyrosine kinase inhibitorsHeinz-Josef Klümpen, Caroline F Samer, Ron H J Mathijssen, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 14, 2018
Quantitation of the anticancer drug abiraterone and its metabolite Δ(4)-abiraterone in human plasma using high-resolution mass spectrometryAtul Bhatnagar, Matthew J McKay, Megan Crumbaker, et al.
Pageof 14

Showing results (31-40 of 135) with videos related to

Sort By:
Pageof 14
BJU International|July 25, 2013
Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancerAndy C M Won, Howard Gurney, Gavin Marx, et al.
Asia-Pacific Journal of Clinical Oncology|March 3, 2022
Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific regionMasatoshi Eto, Jae-Lyun Lee, Yen-Hwa Chang, et al.
Journal of Mass Spectrometry : JMS|July 30, 2020
Evaluating bioanalytical capabilities of paper spray ionization for abiraterone drug quantification in patient plasmaAtul Bhatnagar, Matthew J McKay, Malmaruha Arasaratnam, et al.
Neuropsychological Rehabilitation|March 4, 2026
Changes in perceived cognitive functioning following a codesigned online group cognitive rehabilitation for prostate cancer survivors on androgen deprivation therapy: Series of single-case experimental designsLorna Pembroke, Kerry A Sherman, Haryana M Dhillon, et al.
Cancer Chemotherapy and Pharmacology|May 14, 2019
Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancerMalmaruha Arasaratnam, Megan Crumbaker, Atul Bhatnagar, et al.
Seminars in Oncology Nursing|July 25, 2024
Online Group Cognitive Rehabilitation Program for Prostate Cancer Survivors: Development Using Codesign and the Theoretical Domains FrameworkLorna Pembroke, Kerry A Sherman, Haryana M Dhillon, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 22, 2024
What is the nature and impact of cognitive difficulties following hormonal treatments for prostate cancer?: An interpretative phenomenological analysisLorna Pembroke, Kerry A Sherman, Haryana M Dhillon, et al.
The Medical Journal of Australia|January 28, 2023
Dual-energy x-ray absorptiometry assessment of bone health in Australian men with prostate cancer commencing androgen deprivation therapyMariya F Hamid, Amy Hayden, Tania Moujaber, et al.
Cancer Treatment Reviews|September 14, 2010
Moving towards dose individualization of tyrosine kinase inhibitorsHeinz-Josef Klümpen, Caroline F Samer, Ron H J Mathijssen, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 14, 2018
Quantitation of the anticancer drug abiraterone and its metabolite Δ(4)-abiraterone in human plasma using high-resolution mass spectrometryAtul Bhatnagar, Matthew J McKay, Megan Crumbaker, et al.
Pageof 14